Back to today’s briefing

Story perspectives

Promising Oral Antibiotic Trial Paused Amid Success

5/29/2025

32 5

Summary

Story summary

GSK Plc. and Spero Therapeutics have paused their promising trial of tebipenem HBr for urinary tract infections after meeting key efficacy goals. Involving 1,690 patients, the study revealed that tebipenem HBr performed on par with traditional intravenous treatments. If greenlit, it could become the first oral carbapenem antibiotic for complicated UTIs in the US, tackling the urgent issue of antimicrobial resistance.

1 of 1

Story summary

GSK Plc. and Spero Therapeutics have paused their promising trial of tebipenem HBr for urinary tract infections after meeting key efficacy goals. Involving 1,690 patients, the study revealed that tebipenem HBr performed on par with traditional intravenous treatments. If greenlit, it could become the first oral carbapenem antibiotic for complicated UTIs in the US, tackling the urgent issue of antimicrobial resistance.